CLINICAL AND EPIDEMIOLOGICAL RESEARCH

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

R Fleischmann¹, J Vencovsky², R F van Vollenhoven³, D Borenstein⁴, J Box⁵, G Coteur⁶, N Goel⁷, H-P Brezinschek⁸, A Innes⁹, V Strand¹⁰

¹ University of Texas Southwestern Medical Center, Dallas, Texas, USA
² Institute of Rheumatology, Prague, Czech Republic
³ Karolinska Institute, Stockholm, Sweden
⁴ George Washington University Medical Center, Washington, DC, USA
⁵ Carolina Bone and Joint, Charlotte, North Carolina, USA
⁶ UCB, Braine l’Alleud, Belgium
⁷ UCB, Atlanta, Georgia, USA
⁸ Medical University Graz, Graz, Austria
⁹ UCB, Slough, UK
¹⁰ Stanford University, Stanford, California, USA

R Fleischmann, University of Texas Southwestern Medical Center, 5939 Harry Hines Blvd., Dallas, Texas 75235, USA; rfleischmann{at}arthdocs.com

Background: Tumour necrosis factor (TNF) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid arthritis (RA). Treatment with TNF inhibitors reduces disease activity and improves outcomes for patients with RA. This study evaluated the efficacy and safety of certolizumab pegol 400 mg, a novel, poly-(ethylene glycol) (PEG)ylated, Fc-free TNF inhibitor, as monotherapy in patients with active RA.

Methods: In this 24-week, multicentre, randomised, double-blind, placebo-controlled study, 220 patients previously failing 1 disease-modifying antirheumatic drug (DMARD) were randomised 1:1 to receive subcutaneous certolizumab pegol 400 mg (n = 111) or placebo (n = 109) every 4 weeks. The primary endpoint was 20% improvement according to the American College of Rheumatology criteria (ACR20) at week 24. Secondary endpoints included ACR50/70 response, ACR component scores, 28-joint Disease Activity Score Erythrocyte Sedimentation Rate 3 (DAS28(ESR)3), patient-reported outcomes (including physical function, health-related quality of life (HRQoL), pain and fatigue) and safety.

Results: At week 24, the ACR20 response rates were 45.5% for certolizumab pegol 400 mg every 4 weeks vs 9.3% for placebo (p<0.001). Differences for certolizumab pegol vs placebo in the ACR20 response were statistically significant as early as week 1 through to week 24 (p<0.001). Significant improvements in ACR50, ACR components, DAS28(ESR)3 and all patient-reported outcomes were also observed early with certolizumab pegol and were sustained throughout the study. Most adverse events were mild or moderate and no deaths or cases of tuberculosis were reported.

Conclusions: Treatment with certolizumab pegol 400 mg monotherapy every 4 weeks effectively reduced the signs and symptoms of active RA in patients previously failing 1 DMARD compared with placebo, and demonstrated an acceptable safety profile.

Trial registration number: NCT00548834.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

David L Scott and Andrew Cope
Ann Rheum Dis 2009 68: 767-769. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Scott, D. L, Cope, A. (2009). New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?. Ann Rheum Dis 68: 767-769 [Full Text]